Kymera Therapeutics Tech Stack

Clinical-stage biotech developing oral protein-degradation medicines

Biotechnology Research Watertown, MA 51–200 employees Founded 2016 Public Company

Kymera is a clinical-stage biotechnology company advancing targeted protein degradation (TPD) as a new therapeutic modality. The hiring velocity is accelerating across research, healthcare, data, and manufacturing—with 20 roles posted in the last 30 days and a pronounced leadership tier (11 directors, 11 senior roles, 2 VPs)—signaling active scaling toward multi-program clinical execution. Active projects span global trial execution, endpoint management, clinical data systems, and analytical method development, while pain points center on data quality, hybrid identity infrastructure, and supply-chain reliability.

Tech Stack 21 technologies

Core StackIntune Python AWS Terraform CloudFormation Azure Entra ID Azure AD Connect Exchange Online OneDrive Spotfire Benchling CDISC MaxQuant HPLC LC-MS Azure Entra SD-WAN VPN Veeva RIM

What Kymera Therapeutics Is Building

◆Challenges

Ensuring data quality compliance
Hybrid identity issues
Ensuring reliable supply
Standardizing data across multiple systems
Improving data collection processes
Managing outsourced data management deliverables
Vendor relationship management
Streamlining proteomics workflows
Ensuring assay reproducibility
Cloud migration of endpoint management

▲Active Projects

Targeted proteomics workflow development
Global clinical trial execution
Endpoint management & intune support package
Registration and validation campaigns
Clinical data activities on ecoa and irt
Clinical systems roadmap
Clinical assay qualification
Stage-gated readiness programs
Enterprise portfolio planning
Critical analytical method development

Hiring Activity

Accelerating25 roles · 20 in 30d

Department

Research

Healthcare

Data

Ops

Manufacturing

Operations

Support

Seniority

Director

Senior

Principal

Notable leadership hires: Medical Director

Company intelligence

Find more companies like Kymera Therapeutics by tech stack, pain points and active projects

Get started free

About Kymera Therapeutics

Kymera is a public, clinical-stage biotechnology company headquartered in Watertown, MA, founded in 2016. The company pioneers targeted protein degradation to address disease targets inaccessible to conventional therapeutics, with a focus on oral small-molecule degraders for immunological diseases. Kymera has advanced the first TPD degrader into clinical trials. The tech stack reflects a mature clinical biotech operation: Benchling for lab workflows, Veeva RIM for regulatory, CDISC and MaxQuant for data standardization, AWS/Azure for compute, and Intune/Entra for enterprise identity. The company operates across research, clinical development, data science, manufacturing, and operations, with current hiring emphasis on director and senior-level positions across all functions.

HeadquartersWatertown, MA

Company Size51–200 employees

Founded2016

Hiring MarketsUnited Kingdom

Frequently Asked Questions

What is Kymera Therapeutics developing?

Kymera develops oral small-molecule medicines using targeted protein degradation (TPD) for immunological diseases. The company has advanced its first TPD degrader into clinical trials and is focused on addressing disease targets previously inaccessible with conventional therapeutics.

What tech stack does Kymera use?

Kymera uses Benchling for lab workflows, Veeva RIM for regulatory management, CDISC and MaxQuant for data analysis, LC-MS and HPLC for analytical chemistry, AWS/Azure for cloud infrastructure, and Intune/Entra for identity and endpoint management.

How this profile is built

Kymera Therapeutics's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →

This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.